Margarida Serra’s team from the Instituto de Biologia Experimental e Tecnológica has potentially improved the development of liver disease treatments by controlling the oxygen levels in bioreactors to produce more hepatocyte-like cells (HLCs). Current methods generate low numbers of HLCs, but the research found that reducing oxygen levels to 4% boosts number and differentiation of HLCs, setting the stage for future liver disease treatments.
Mark Cuban says Cost Plus Drugs will partner with TrumpRx
Cost Plus Drugs is sharing pricing data with TrumpRx, the administration’s new direct-to-consumer prescription drug website set to launch next year.
